Novavax's Q2 2026: Milestones, Revenue Framing and the Sanofi Pivot

Second Quarter 2026: What happened

• Total revenue for the quarter: $57 million, down 76% from the $239 million reported in the same period last year. The prior year benefited from a $202 million lift tied to a milestone and related licensing activity.
• Nuvaxovid product sales: $0 in Q2 2026 (versus $0.2 million? implied in prior-year framing); the headliner here is the absence of direct product revenue this quarter as Sanofi assumes broader market commercialization in select locales.
• Supply sales: $19 million, up from $13 million a year ago (+47%), reflecting continued adjuvant and ancillary sales through partner channels.
• Product sales: $19 million, up from $11 million in Q2 2025 (about +76%), driven by Matrix-M adjuvant demand and partner-funded distribution.
• Licensing, royalties and other revenue: $38 million versus $229 million in the prior year, a result of the high 2025 milestone and licensing activity (notably with Sanofi and Takeda).
• Sanofi line: revenue recognized under the Sanofi license was $36 million in Q2 2026, down sharply from $199 million in Q2 2025 (an 82% drop), underscoring the lumpy nature of milestone-driven licensing.
• R&D and SG&A: R&D expenses were $71 million (with $23 million reimbursed by partners), and non-GAAP R&D, net of partner reimbursement, was $48 million; SG&A totaled $27 million, a 39% year-over-year reduction.
• Net income / loss: a net loss of $53 million for the quarter, compared with net income of $107 million in the prior-year period (the prior year benefited from the $202 million milestone mix described above).
• Liquidity: cash, cash equivalents, marketable securities and restricted cash totaled $724 million as of June 30, 2026, versus $751 million at year-end 2025.

Revenue framework and guidance for 2026

Novavax updated its full-year 2026 expectations, outlining a revenue framework that excludes certain Sanofi-driven forecast components while emphasizing partner-driven top-line dynamics. The company now sees:

Nuvaxovid product sales

$35–$45 million for 2026 (as of Aug 6, 2026; prior visibility unchanged for this line).

Adjusted Supply Sales

$45–$55 million (vs. the prior window of $40–$50 million).

Adjusted Licensing, Royalties and Other Revenue

$155–$175 million

Adjusted Total Revenue

$235–$275 million

Notes accompany the framework: Sanofi supply sales, Sanofi royalties, and Sanofi milestones carry no formal 2026 guidance in this update. The revenue framework is a view on Novavax’s ability to generate cash and recurring revenue in a world where Sanofi remains the commercialization engine for select markets.

From a working-capital and investor-relations angle, the framework emphasizes milestones and collaboration economics more than standalone per-share earnings. In practice, this means the classic EPS debate remains subtle: the company continues to post a GAAP net loss for the quarter, and there is limited publicly disclosed EPS guidance. The absence of a quarterly EPS surprise signal from a formal consensus means the market is left to infer the impact of milestones and partner-driven revenue on its earnings trajectory.

Milestones, partnerships and the path forward

The press release reiterates several milestones that anchor the revenue story:

• Sanofi collaboration: Sanofi intends to be among the first-mover partners in the COVID-19-Influenza Combination (CIC) vaccine segment; initiation of this U.S./EU trial will trigger a $125 million milestone to Novavax.
• Manufacturing technology transfer: Completion of the transfer to Sanofi for Nuvaxovid is expected in mid-2027 and would trigger a $75 million milestone payment to Novavax.
• Commercial expansion: Sanofi is expanding Nuvaxovid’s commercial reach in the U.S. and several other markets (UK, Germany, Canada) from 2026 onward, with Novavax eligible for royalties in the high-teens to low-twenties as a share of Sanofi’s global net sales.
• Scientific validation: A growing body of evidence supports Matrix-M’s utility in oncology and infectious diseases, underpinning future licensing opportunities.
• C. difficile vaccine program: Advanced into pre-IND discussions with the FDA and GMP manufacturing, with potential clinical entry as early as 2027.

What this could portend for NVAX and peers

The quarter underscores a broader theme in biotech: the revenue line is increasingly a function of partnerships and milestone choreography rather than pure product sales. For NVAX, the key questions are whether the Sanofi-driven commercial cadence can steadily convert milestones into durable cash flow and whether the 2026 revenue framework can translate into sustainable profitability as Nuvaxovid gains broader licensing and adjuvant demand.

From a sector perspective, the story highlights several dynamics relevant to peers:

• Milestone-rich licensing arrangements can yield outsized year-to-year volatility; investors should watch for the cadence of milestone recognition and regulatory triggers rather than quarterly product revenue alone.
• Transitioning commercial responsibility to a large partner can unlock scale but concentrates earnings risk in partner performance and forecasting accuracy.
• Non-GAAP adjustments and reimbursements from partners matter meaningfully for cash flow and reported operating costs; these items can obscure underlying operating trends if not monitored carefully.

Key takeaways for readers

1. The quarter delivers a stark reminder that a vaccine company’s revenue profile can hinge on milestone milestones more than mid-quarter product sales alone.
2. The 2026 revenue forecast calls for a measured uplift from the Q2 base, driven by adjusted supply and licensing revenue rather than near-term Nuvaxovid product revenue, which remains a Sanofi-led variable.
3. Quadrant-wise, the company’s EPS story is negative on a GAAP basis for the quarter, but the EPS-consensus narrative will depend on how investors value the milestone stream and the progress toward the 2027 manufacturing-transfer milestone.
4. For sector peers, the message is clear: partnerships can be a double-edged sword—accelerating reach while compressing earnings visibility into milestone timing and partner performance.